Introduction: The metabolic syndrome is increasingly recognized as a powerful predictor of patient risk for developing cardiovascular and cerebrovascular complications. It is viewed as the phenotypic confluence of atherogenic dyslipidaemia, hypertension, central obesity and insulin resistance (with or without type 2 diabetes) resulting from dysregulated gene expression and lifestyle behaviours.
Aim: Because insulin resistance is a core defect in type 2 diabetes and the metabolic syndrome and may cause the atherogenic dyslipidaemia, the aim of the study was to establish a possible correlation between INSR His1085 (C/C, C/T, T/T) and IRS1 Gly972Arg (G/G, G/A, A/A) genetic variability and levels of triglycerides, high-density lipoprotein cholesterol (HDL-C) and small dense low-density lipoprotein (LDL) particles.
Methods: We enrolled 214 patients (125 men and 89 women) average age of 66±10 years with average duration of type 2 diabetes and metabolic syndrome of 9 years (513). Genomic DNA was extracted from peripheral blood leukocytes while analysis of His1085 and Gly972Arg gene mutations was performed with PCR restriction fragment length polymorphism method (PCR-RFLP). Lipid parameters were determined on an automatic analyzer using original reagents for measurement.
Results: We did not found statistical significance between carriers of examined genotypes and levels of lipid parameters.
Conclusion: Our study has shown that the INSR His1085 (C/C, C/T, T/T) and IRS1 Gly972Arg (G/G, G/A, A/A) genetic variability is not associated with different lipid profile of the examinees.
30 Apr - 04 May 2011
European Society of Endocrinology